This study is being done to collect medical and personal histories as well as a samples of blood, other body fluid and/or tumor/disease tissue for current and future research studies on histiocytic disorders.
PRIMARY OBJECTIVES: I. Define molecular signature and genomic landscape of histiocytic disorders. II. Correlate genomic findings with transcriptional abnormalities. III. Identify promising prognostic alterations and potential therapeutic targets. OUTLINE: This is an observational study. Patients complete questionnaires and undergo blood and tissue sample collection. Patients' medical records are also reviewed.
Study Type
OBSERVATIONAL
Enrollment
500
Non-interventional study
Mayo Clinic in Rochester
Rochester, Minnesota, United States
RECRUITINGIdentify molecular markers
Biopsy samples will be analyzed for the presence of molecular markers associated with histiocytic disorders. Potential markers include BRAF V600E, cyclinD1, PD-L1, p16, and p53.6. For any test results that are actionable, patients will be notified and the results will be available in the electronic medical record.
Time frame: Baseline
Change in PD-L1 and T-cell Bim expression
Blood testing will be performed for soluble PD-L1 and T-cell Bim expressions before and after radiation therapy for histiocytic disease to assess change in levels and role of immunotherapy. For any test results that are actionable, patients will be notified and the results will be available in the electronic medical record.
Time frame: Baseline; post-treatment (estimated up to 2 years, potentially 4 times per year)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.